Patents by Inventor Bart Vanhaesebroeck

Bart Vanhaesebroeck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9747412
    Abstract: The present invention provides a method for identifying differential activation of a bisubstrate protein modifying enzyme between samples, comprising: (i) incubating a first sample with x different concentrations of the non-protein substrate of said enzyme, wherein x is 2 or greater than 2; (ii) quantifying modification of a polypeptide in said sample at each of the x different concentrations of the non-protein substrate; (iii) determining the affinity of said enzyme for said non-protein substrate; (iv) repeating steps (i) to (iii) for a second or subsequent sample; and (v) comparing the affinity of said enzyme for said non-protein substrate between said samples; wherein a difference in affinity of said enzyme for said non-protein substrate between samples is indicative of differential activation of said enzyme between samples. The present invention also provides a method for identifying an in vivo substrate of a bisubstrate protein modifying enzyme.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: August 29, 2017
    Assignee: HVIVO SERVICES LIMITED
    Inventors: Pedro Rodriguez Cutillas, Bart Vanhaesebroeck, Luisa Marie Beltran
  • Patent number: 9110076
    Abstract: The present invention provides a method for quantifying modified peptides in a sample, the method comprising: (a) obtaining peptides from the sample; (b) adding reference modified peptides to the peptides obtained in step (a) to produce a mixture of peptides and reference modified peptides; (c) carrying out mass spectrometry (MS) on said mixture of peptides and reference modified peptides to obtain data relating to the peptides in the sample; and (d) comparing the data relating to the peptides in the sample with data in a database of modified peptides using a computer program; wherein the database of modified peptides is compiled by a method comprising: (i) obtaining peptides from a sample; (ii) enriching modified peptides from the peptides obtained in step (i); (iii) carrying out liquid chromatography-tandem mass spectrometry (LC-MS/MS) on the enriched modified peptides obtained in step (ii); (iv) comparing the modified peptides detected in step (iii) to a known reference database in order to identify the mo
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: August 18, 2015
    Assignee: HVIVO SERVICES LIMITED
    Inventors: Pedro Rodriguez Cutillas, Bart Vanhaesebroeck
  • Publication number: 20130303386
    Abstract: The present invention provides a method for identifying differential activation of a bisubstrate protein modifying enzyme between samples, comprising: (i) incubating a first sample with x different concentrations of the non-protein substrate of said enzyme, wherein x is 2 or greater than 2; (ii) quantifying modification of a polypeptide in said sample at each of the x different concentrations of the non-protein substrate; (iii) determining the affinity of said enzyme for said non-protein substrate; (iv) repeating steps (i) to (iii) for a second or subsequent sample; and (v) comparing the affinity of said enzyme for said non-protein substrate between said samples; wherein a difference in affinity of said enzyme for said non-protein substrate between samples is indicative of differential activation of said enzyme between samples. The present invention also provides a method for identifying an in vivo substrate of a bisubstrate protein modifying enzyme.
    Type: Application
    Filed: October 18, 2011
    Publication date: November 14, 2013
    Inventors: Pedro Rodriguez Cutillas, Bart Vanhaesebroeck, Luisa Marie Beltran
  • Publication number: 20120070844
    Abstract: The present invention provides a method for quantifying modified peptides in a sample, the method comprising: (a) obtaining peptides from the sample; (b) adding reference modified peptides to the peptides obtained in step (a) to produce a mixture of peptides and reference modified peptides; (c) carrying out mass spectrometry (MS) on said mixture of peptides and reference modified peptides to obtain data relating to the peptides in the sample; and (d) comparing the data relating to the peptides in the sample with data in a database of modified peptides using a computer programme; wherein the database of modified peptides is compiled by a method comprising: (i) obtaining peptides from a sample; (ii) enriching modified peptides from the peptides obtained in step (i); (iii) carrying out liquid chromatography-tandem mass spectrometry (LC-MS/MS) on the enriched modified peptides obtained in step (ii); (iv) comparing the modified peptides detected in step (iii) to a known reference database in order to identify the
    Type: Application
    Filed: April 16, 2010
    Publication date: March 22, 2012
    Applicant: QUEEN MARY & WESTFIELD COLLEGE
    Inventors: Pedro Rodriguez Cutillas, Bart Vanhaesebroeck
  • Publication number: 20110281289
    Abstract: The disclosure relates to methods of analyzing the enzymatic activity of enzymes in samples containing a plurality of enzymes, using mass spectrometry. Immobilized substrates are employed. Purified enzymes and enzymes from crude cell lysates can be analyzed using the disclosed methods.
    Type: Application
    Filed: July 13, 2009
    Publication date: November 17, 2011
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
    Inventors: Pedro Cutillas, Bart Vanhaesebroeck
  • Publication number: 20090215098
    Abstract: The disclosure relates to methods of quantitatively analyzing the enzymatic activity of enzymes in samples containing a plurality of enzymes, using mass spectrometry. Isotopically labeled standards are employed. Purified enzymes and enzymes from crude cell lysates may be analyzed using the disclosed methods. As little as 0.02 pg of cell lysate may be detected. Also disclosed are kits for providing compositions so as to practice the disclosed methods.
    Type: Application
    Filed: April 25, 2007
    Publication date: August 27, 2009
    Applicants: UCL BUSINESS PLC., LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Pedro Rodriguez Cutillas, Bart Vanhaesebroeck
  • Publication number: 20060018893
    Abstract: The invention relates to a novel lipid kinase which is part of the PI3 Kinase family. PI3 Kinases catalyze the addition of phosphate to inositol generating inositol mono, di and triphosphate. Inositol phosphates have been implicated in regulating intracellular signaling cascades resulting in alternations in gene expression which, amongst other effects, can result in cytoskeletal remodeling and modulation of cellular motility. More particularly the invention relates to a novel human PI3 Kinase, p110? which interacts with p85, has a broad phosphinositide specificity and is sensitive to the same kinase inhibitors as P13 Kinase p110A. However, in contrast to previously identified PI3 Kinases which show a ubiquitous pattern of expression, p110? is selectively expressed in leucocytes. Importantly, p110? shows enhanced expression in most melanomas tested and therefore may play a crucial role in regulating the metastatic property exhibited by melanomas.
    Type: Application
    Filed: September 2, 2005
    Publication date: January 26, 2006
    Inventors: Bart Vanhaesebroeck, Michael Waterfield
  • Publication number: 20050064572
    Abstract: The invention relates to a novel lipid kinase which is part of the PI3 Kinase family. PI3 Kinases catalyze the addition of phosphate to inositol generating inositol mono, di and triphosphate. Inositol phosphates have been implicated in regulating intracellular signaling cascades resulting in alternations in gene expression which, amongst other effects, can result in cytoskeletal remodeling and modulation of cellular motility. More particularly the invention relates to a novel human PI3 Kinase, p110? which interacts with p85, has a broad phosphinositide specificity and is sensitive to the same kinase inhibitors as PI3 Kinase p110A. However, in contrast to previously identified PI3 Kinases which show a ubiquitous pattern of expression, p110? is selectively expressed in leucocytes. Importantly, p110? shows enhanced expression in most melanomas tested and therefore may play a crucial role in regulating the metastatic property exhibited by melanomas.
    Type: Application
    Filed: August 20, 2004
    Publication date: March 24, 2005
    Inventors: Bart Vanhaesebroeck, Michael Waterfield
  • Publication number: 20030099627
    Abstract: The invention relates to a novel lipid kinase which is part of the PI3 Kinase family. PI3 Kinases catalyze the addition of phosphate to inositol generating inositol mono, di and triphosphate. Inositol phosphates have been implicated in regulating intracellular signaling cascades resulting in alternations in gene expression which, amongst other effects, can result in cytoskeletal remodeling and modulation of cellular motility. More particularly the invention relates to a novel human PI3 Kinase, p110&Dgr; which interacts with p85, has a broad phosphinositide specificity and is sensitive to the same kinase inhibitors as PI3 Kinase p110A. However, in contrast to previously identified PI3 Kinases which show a ubiquitous pattern of expression, p110&Dgr; is selectively expressed in leucocytes. Importantly, p110&Dgr; shows enhanced expression in most melanomas tested and therefore may play a crucial role in regulating the metastatic property exhibited by melanomas.
    Type: Application
    Filed: June 3, 2002
    Publication date: May 29, 2003
    Inventors: Bart Vanhaesebroeck, Michael Derek Waterfield
  • Patent number: 6482623
    Abstract: The invention relates to a novel lipid kinase which is part of the PI3 Kinase family. PI3 Kinases catalyze the addition of phosphate to inositol generating inositol mono, di and triphosphate. Inositol phosphates have been implicated in regulating intracellular signalling cascades resulting in alternations in gene expression which, amongst other effects, can result in cytoskeletal remodelling and modulation of cellular motility. More particularly the invention relates to a novel human PI3 Kinase, p110&dgr; which interacts with p85, has a broad phosphoinositide specificity and is sensitive to the same kinase inhibitors as PI3 Kinase p110&agr;. However in contrast to previously identified PI3 Kinases which show a ubiquitous pattern of expression, p110&dgr; is selectively expressed in leucocytes. Importantly, p110&dgr; shows enchanced expression in most melanomas tested and therefore may play a crucial role in regulating the metastatic property exhibited by melanomas.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: November 19, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Bart Vanhaesebroeck, Michael Derek Waterfield